# A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers

> **NCT06577298** · PHASE1,PHASE2 · RECRUITING · sponsor: **CanSino Biologics Inc.** · enrollment: 480 (estimated)

## Conditions studied

- Poliomyelitis

## Interventions

- **BIOLOGICAL:** Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio) low adjuvant dose
- **BIOLOGICAL:** VLP-Polio medium dose
- **BIOLOGICAL:** VLP-Polio high dose
- **BIOLOGICAL:** Vaccine Poliomyelitis Inactivated (IPV)

## Key facts

- **NCT ID:** NCT06577298
- **Lead sponsor:** CanSino Biologics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-19
- **Primary completion:** 2026-10
- **Final completion:** 2026-12
- **Target enrollment:** 480 (ESTIMATED)
- **Last updated:** 2025-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06577298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06577298, "A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06577298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*